drug · antibody
brolucizumab
Phase 3updated 3mo agoby $NVS NOVARTIS AG🔗 ChEMBL
Phase 3community read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 5 investigational indications.
indications
indications
Diabetic Macular Edema
targets
Vascular endothelial growth factor A, long form
all catalysts(0)
nothing on the calendar yet
Trials studying brolucizumab
- —Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
- phase4Post Marketing Study to Evaluate the Safety and Effectiveness of Brolucizumab in Patients With Diabetic Macular Edema.
- phase3Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy
- phase3Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
- phase4Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration
- —Special Drug Use Observational Study With Beovu Kit for Intravitreal Injection
- phase4Brolucizumab Efficacy and Safety Single-Arm Descriptive Trial in Patients With Persistent Diabetic Macular Edema
- phase4Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.
News(1)
- EyePoint plummets on pivotal data for main drugThough its drug missed the main goal of a wet AMD study, EyePoint, as well as analysts, still see a path toward approval. Investors may be harder to win over, however.biopharma_dive · 4h ago
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that